Literature DB >> 3638931

Interaction between rifampin and fusidic acid against methicillin-resistant coagulase-positive and -negative staphylococci.

B F Farber, Y C Yee, A W Karchmer.   

Abstract

We studied the interaction between rifampin and fusidic acid against a group of staphylococci. Of the 20 coagulase-positive strains studied, checkerboard studies revealed synergy in 3 and indifference in 17; time-kill studies revealed synergy in 18 of 19 coagulase-positive strains at both 24 and 48 h. Of the 19 coagulase-negative strains, checkerboard studies revealed synergy in 6 and indifference in 13; time-kill studies revealed synergy in 6 of 18 coagulase-negative strains at 24 h and in 17 of 18 coagulase-negative strains at 48 h. The combination of rifampin and fusidic acid warrants further evaluation in the therapy of staphylococcal disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3638931      PMCID: PMC176459          DOI: 10.1128/AAC.30.1.174

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Fucidin-resistant staphylococci in current hospital practice.

Authors:  J R Pattison; P E Mansell
Journal:  J Med Microbiol       Date:  1973-05       Impact factor: 2.472

2.  In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus.

Authors:  M Foldes; R Munro; T C Sorrell; S Shanker; M Toohey
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

3.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

4.  In vitro activity of combinations of antibiotics against Staphylococcus aureus resistant to gentamicin and methicillin.

Authors:  S Dixson; W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1985 Jan-Feb       Impact factor: 3.553

5.  Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy.

Authors:  A W Karchmer; G L Archer; W E Dismukes
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

6.  Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.

Authors:  B F Farber; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

  6 in total
  5 in total

1.  Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae.

Authors:  S G Franzblau; A N Biswas; E B Harris
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Pairwise antibiotic interactions in Escherichia coli: triclosan, rifampicin and aztreonam with nine other classes of antibiotics.

Authors:  Caroline Nguyen; Alice Zhou; Ayesha Khan; Jeffrey H Miller; Pamela Yeh
Journal:  J Antibiot (Tokyo)       Date:  2016-03-09       Impact factor: 2.649

Review 3.  Methicillin-resistant staphylococci.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Clinical trial of fusidic acid for lepromatous leprosy.

Authors:  S G Franzblau; G P Chan; B G Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; R F Calvo; D L Williams; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 5.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.